Sometimes it just makes the dossier longer. Companies can generate extensive CMC data and still receive fundamental questions during regulatory assessment.
Why?
Because the data were generated without first defining the regulatory conclusion they needed to support.
– A specification is introduced because “QA expects it.”
– A method is fully validated because “validation is required.”
– Three batches are tested because “regulators expect three batches.”
– Additional supplier documentation is collected because “we probably need it for the dossier.”
Each activity may be reasonable. But unless the activities are connected by a clear regulatory rationale, they do not automatically create a convincing submission.
A strong CMC package should follow a visible line of reasoning:
Risk → scientific justification → control strategy → evidence → specification → regulatory conclusion
This is particularly important for:
– Starting-material selection under ICH Q11
– Analytical procedure development and validation under ICH Q14 and Q2(R2)
– Impurity and residual-solvent control
– Manufacturing process changes
– Late-stage changes to materials, suppliers or control strategies
The critical distinction is this:
Regulatory readiness is not the same as documentation completeness. A company can have a folder full of reports and still be unable to answer the assessor’s central question: How does this evidence support the proposed control strategy and the regulatory conclusion?
Before commissioning another study or requesting another document, ask: What exactly must be demonstrated, and will the planned evidence demonstrate it?
Identifying that gap during development creates options. Discovering it during assessment creates regulatory questions, additional work and potentially avoidable delays.
Starodub helps pharmaceutical companies identify weaknesses in their CMC strategy before those weaknesses become regulatory findings. Preparing a submission, responding to an authority question or planning a significant CMC change?
Contact Starodub at info@starodub.nl to discuss whether the regulatory argument is as strong as the underlying science.
